Pfizer antiviral pill could be risky with other widely used medications

"Some of these potential interactions are not trivial, and some pairings have to be avoided altogether," Peter Anderson, a professor of pharmaceutical sciences at the University of Colorado told NBC News.
[...]
In a statement to The Hill, a Pfizer spokesperson said, "The potential for drug-drug interactions (DDI) for Paxlovid was examined in a series of in vitro studies, as well as clinical DDI studies [AKA adverse events (AEs) AKA adverse drug reactions (ADRs)]."

WHICH clinical studies of WHICH drugs and WHICH study criteria--latitudinal, longitudinal, medical history, "end-points," sample size, etc?

The spokesperson further elaborated on the antiviral pill and said that Paxlovid is comprised of the active  protease inhibitor Nirmatrelvir [total mg p.d.?], as well as a low-dose of 100 mg of Ritonavir [total mg p.d.?].  

"Its effect on drug metabolism may result in drug interactions, and some drugs may be contra-indicated. However, in light of the fact that Paxlovid has a short duration of treatment of five days [Rx "course" ≠ active ingredient half-life], combined with a low dose of Ritonavir of 100 milligrams, we believe that healthcare professionals [sic; s/b patients] should find most DDIs to be generally manageable ["tolerable"]," the statement reads.

supra ya think
immunomodulating industry; half-life, wash-out period